Reportlinker.com

Reportlinker.com

April 16, 2008 05:01 ET

High Growth Reported for the Emerging Pharmaceutical Markets Argentina and Mexico

LONDON, UNITED KINGDOM--(Marketwire - April 16, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.

Emerging pharmaceutical markets Argentina and Mexico

http://www.reportlinker.com/p087052/Emerging-pharmaceutical-markets-Argentina-and-Mexico.html

Introduction

Latin American countries have attracted a lot of attention recently. With their economies currently stable, their geographic location and low-cost is ideal for investors. In addition, having such a high and varied population eases recruitment for clinical trials, and the demographics show there is a very high need for pharmaceuticals.

Scope

- Overview of the key trends driving the pharmaceutical market growth

- Analysis of key healthcare system characteristics impacting the pharmaceutical market

- Analysis of pharmaceutical market dynamics in Argentina and Mexico

- Overview of key pharmaceutical players in Argentina and Mexico

Highlights

Although both the Argentinean and the Mexican markets have been growing, their growth is attributed to different reasons. The Argentinean pharmaceutical market has been growing mainly based on growing sales volume, while growth of the Mexican market is mainly driven by growing prices.

The Mexican market is dominated by foreign companies with few domestic players. The Argentinean market is dominated by domestic branded generics firms, due to the economic crisis which led to many foreign companies to sell their plants in Argentina, thus allowing the domestic firms to gain over their market share.

Sales of pharmaceutical categories in both countries are very similar to the West thus opening growth opportunities for foreign companies. However, sales of oncology drugs are low in both countries; and Mexico has higher sales of anti-infective drugs indicating that these markets still have scope for further development and growth.

Reasons to Purchase

- Identify the healthcare needs in Argentina and Mexico

- Understand the barriers and drivers for entering these markets

- Gain insight into pharmaceutical dynamics of Argentina and Mexico

CHAPTER 1 EXECUTIVE SUMMARY 4

Scope of the report 4

Key findings 4

Argentina 4

Mexico 5

IMS caveat 6

CHAPTER 2 THE PHARMACEUTICAL MARKET IN ARGENTINA 11

Argentina has stable macroeconomic factors, some of which must be strengthened 11

A growing pharmaceutical market dominated by branded generics 12

Demographic trends in Argentina 13

Disease burden in Argentina 14

Socioeconomic environment in Argentina 15

Political climate in Argentina - stable 15

GDP has been growing after the economic crisis of 2001 16

Regional differences - the fight for equality continues 17

Mercosur established free trade between the countries involved 18

Corporate environment in Argentina 19

Foreign direct investment in Argentina is modest 19

Taxation system in Argentina 19

The healthcare system in Argentina 21

Healthcare expenditure in Argentina is high 23

The public sector is decentralized 23

Social health insurance system is fragmented 24

The private sector covers a minority of the population 25

The hospital capacity within the public sector has declined while the private sector has been growing 25

Regulatory issues in Argentina 26

IP protection has improved but is still inadequate 26

A significant effort has been made to reduce the patent backlog in Argentina 27

Registration of drugs in Argentina is a straight forward procedure 28

Advertising of pharmaceuticals is strictly controlled 28

Import of pharmaceuticals has been facilitated by Mercosur agreement 29

Drug counterfeiting has been reduced by a number of measures 29

Pricing and reimbursement of pharmaceuticals in Argentina 30

Pricing of pharmaceuticals in Argentina 30

The Generics Law, resulted in lower prices and increased access to pharmaceuticals 30

Antiretroviral therapy prices were decreased 31

Reimbursement of pharmaceuticals in Argentina 32

Remediar program, introduced in 2002, increased drug access to the poor 33

Pharmaceutical market dynamics in Argentina 34

Branded generics dominate the Argentinean market 35

Top three distributors dominate while retail pharmacy chains are expanding 37

Top manufacturers on the Argentinean retail market 38

Top ATC groups by sales value on the Argentinean retail market 39

Top brands on the Argentinean retail market 42

Import and export of pharmaceuticals - demand for foreign drugs remains high 43

Major foreign pharmaceutical companies in Argentina 43

Pfizer 43

Bayer 44

Roche 44

Major domestic pharmaceutical companies in Argentina 44

Roemmers 45

Bago - collaboration and geographical expansion are driving growth 45

Phoenix 46

Clinical trials in Argentina - an underused opportunity 47

CHAPTER 3 THE PHARMACEUTICAL MARKET IN MEXICO 51

Growth of the Mexican economy and strengthened intellectual property rights are boosting pharma industry 51

The Mexican pharmaceutical market is dominated by foreign companies and is attracting a lot of clinical research 52

Demographic trends in Mexico 53

Disease burden in Mexico 54

Socioeconomic environment in Mexico 55

Political climate in Mexico 55

GDP has increased since the introduction of NAFTA 56

Regional differences - some rural areas are in extreme poverty 57

NAFTA eliminated tariffs between the US, Canada and Mexico, and boosted the Mexican economy 57

Corporate environment in Mexico 58

Taxation system in Mexico 58

Foreign direct investment in Mexico was boosted by NAFTA agreement 58

The healthcare system in Mexico 60

Healthcare system reforms in Mexico - the national health system aims to provide choice of healthcare provider 60

Healthcare expenditure in Mexico is low 62

The social security sector 62

Governmental services headed by the Ministry of Health are designed to offer coverage to the poor and uninsured 63

Only a small proportion of the population has private health insurance 63

Regulatory issues in Mexico 64

Intellectual property (IP) protection has significantly improved 64

Registration of drugs in Mexico is simple 65

Physicians play an important role in drug choices 66

Import of pharmaceuticals in Mexico is facilitated by NAFTA 66

Counterfeit drugs are a persistent problem in Mexico 67

Pricing and reimbursement of pharmaceuticals in Mexico 67

Pricing of pharmaceuticals in Mexico 67

Reimbursement in Mexico 69

Pharmaceutical market dynamics in Mexico 73

Mexico classifies generics into three segments 74

Market growth is driven mainly by growing preference and demand for high-value products and not by volume growth 74

Distribution of pharmaceuticals in Mexico is dominated by two distributors 75

Pharmacies selling cheap pharmaceuticals are very popular in Mexico 75

Top pharmaceutical companies in Mexico-multinationals dominate 76

Top ATC groups by sales value on the Mexican retail market 77

Top brands on the Mexican retail market 80

Import and export of pharmaceuticals have increased since NAFTA came into place 81

Major foreign pharmaceutical companies in Mexico 81

Sanofi-Aventis 82

Pfizer 82

AstraZeneca 82

Major domestic pharmaceutical companies in Mexico 83

Senosiain 83

Clinical trials in Mexico - an attractive opportunity for US companies 84

CHAPTER 4 BIBLIOGRAPHY 86

Publications and online articles 86

Datamonitor resources 96

Glossary of Terms 97

List of Tables

Table 1: Demographic indicators for Argentina, 2005 13

Table 2: Average annual growth rate of GDP and exports in Argentina, 1998-2010 (%), 16

Table 3: Key economic indicators for Argentina, 1986-2006 17

Table 4: Health expenditure indicators in Argentina, 2004 23

Table 5: Density of healthcare workers and hospital capacity in Argentina, 1998 26

Table 6: Argentina - Growth of pharmaceutical market in terms of sales volume, 2003-06 35

Table 7: Argentina - Average cost of unit sold, 2003-06 35

Table 8: Branded generics dominate the Argentinean pharmaceutical market, 2006 36

Table 9: Top 15 drug manufacturers in Argentina, 2006 38

Table 10: Market segmentation in Argentina according to ATC groups, 2006 39

Table 11: Top 15 brands in Argentina, 2006 42

Table 12: Key demographic indicators for Mexico, 2005 53

Table 13: Mexico -average annual growth rates of GDP and exports (%), 1986-2010 56

Table 14: Key economic indicators for Mexico, 1986-2006 57

Table 15: Health expenditure indicators in Mexico, 2004 62

Table 16: Growth of the Mexican market in terms of sales volume, 2003-06 74

Table 17: Average cost of unit sold, 2003-06 75

Table 18: Top 15 drug manufacturers in Mexico in 2006 76

Table 19: Growth of ATC group split in the Mexican market, 2006 77

Table 20: Top 15 brands in 2006 in Mexico 80

List of Figures

Figure 1: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical industry in Argentina, 2008 11

Figure 2: Pharmaceutical market dynamics in Argentina, 2008 12

Figure 3: Structure of health system financing and provision in Argentina 22

Figure 4: The size of the Argentinean retail pharmaceutical market, 2002-06 34

Figure 5: Sales growth and CAGR for the top ATC groups in Argentina 40

Figure 6: The relative market share for each ATC group in Argentina is very similar to the six major markets 41

Figure 7: Clinical trial protocols assessed and approved, 1994-2006 48

Figure 8: Multinational pharmaceutical companies sponsor the majority of clinical research in Argentina 49

Figure 9: Advantages and disadvantages of carrying out clinical trials in Argentina 50

Figure 10: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical industry in Mexico 51

Figure 11: Pharmaceutical market dynamics in Mexico 52

Figure 12: The three pricing regulations in Mexico 69

Figure 13: Decision process for listing pharmaceuticals on the Basic Formulary and the Catalogue of Inputs 71

Figure 14: The size of the Mexican retail pharmaceutical market, 2002-06 73

Figure 15: Sales growth and CAGR for the top ATC groups in Mexico, 2006 78

Figure 16: The relative market shares of each ATC groups are very similar between Mexico and the six major markets 79

Figure 17: Advantages and disadvantages of carrying out clinical trials in Mexico 85

To order this report:

Emerging pharmaceutical markets Argentina and Mexico

http://www.reportlinker.com/p087052/Emerging-pharmaceutical-markets-Argentina-and-Mexico.html

More market research reports here!

Contact Information